These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 19532079)
1. HIV entry: new insights and implications for patient management. Hughes A; Nelson M Curr Opin Infect Dis; 2009 Feb; 22(1):35-42. PubMed ID: 19532079 [TBL] [Abstract][Full Text] [Related]
2. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629 [TBL] [Abstract][Full Text] [Related]
3. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865 [TBL] [Abstract][Full Text] [Related]
4. HIV type 1 tropism and inhibitors of viral entry: clinical implications. Weber J; Piontkivska H; Quiñones-Mateu ME AIDS Rev; 2006; 8(2):60-77. PubMed ID: 16848274 [TBL] [Abstract][Full Text] [Related]
6. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1. Ndegwa S Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399 [TBL] [Abstract][Full Text] [Related]
7. [Viral entry as therapeutic target. Current situation of entry inhibitors]. Arenzana-Seisdedos F Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():5-11. PubMed ID: 19133215 [TBL] [Abstract][Full Text] [Related]
8. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications]. Azevedo-Pereira JM; Santos-Costa Q Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693 [TBL] [Abstract][Full Text] [Related]
9. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies. Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135 [TBL] [Abstract][Full Text] [Related]
10. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions. Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908 [TBL] [Abstract][Full Text] [Related]
11. Targeting HIV attachment and entry for therapy. Strizki J Adv Pharmacol; 2008; 56():93-120. PubMed ID: 18086410 [No Abstract] [Full Text] [Related]
12. The epidemiology of HIV coreceptor tropism. Hoffmann C Eur J Med Res; 2007 Oct; 12(9):385-90. PubMed ID: 17933718 [TBL] [Abstract][Full Text] [Related]
13. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Wilkin TJ; Su Z; Kuritzkes DR; Hughes M; Flexner C; Gross R; Coakley E; Greaves W; Godfrey C; Skolnik PR; Timpone J; Rodriguez B; Gulick RM Clin Infect Dis; 2007 Feb; 44(4):591-5. PubMed ID: 17243065 [TBL] [Abstract][Full Text] [Related]